Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Thoracic Malignancies
•
Medical Oncology
Would a patient with a resected NSCLC mass under 3 cm, without lymph node involvement or distant metastases, but with visceral invasion identified on pathology, benefit from adjuvant therapy?
Related Questions
Would a BRAF V600E mutation affect your decision to give adjuvant therapy in a patient with lung cancer?
How does metaplastic thymoma histology impact your decision regarding adjuvant radiation?
In stage IV oligometastatic NSCLC, when considering local consolidative therapies to the primary tumor, do providers typically stage the mediastinum at diagnosis or after initial systemic therapy (assuming no progression)?
Do you offer adjuvant durvalumab for stage I small cell lung cancer following SBRT or surgery?
Would you treat a completely resected Stage IA NSCLC EGFR exon 19 with adjuvant osimertinib alone omitting chemotherapy?
How well does a negative non-contrast MRI of the brain exclude metastasis in a patient with squamous cell carcinoma of the lung?
Would you consider "consolidation" chemoradiotherapy for a Stage III NSCLC that was initially felt to be too extensive for definitive intent radiotherapy who later experiences a radiographic complete response to carboplatin, paclitaxel, and pembrolizumab?
Would you consider starting immunotherapy in a patient with stage IV NSCLC, a high PDL1 level, and active, untreated hepatitis C?
How do you counsel patients with Stage IIIA EGFR+ lung cancer regarding treatment intent with concurrent chemoRT + consolidative systemic therapy?
Would you offer consolidative durvalumab after chemoRT for an isolated mediastinal recurrence of NSCLC that occurred during adjuvant pembrolizumab given for the initial lung cancer?
